Longboard Pharmaceuticals
Biotechnology, 4275 Executive Sq, La Jolla, California, 92037, United States, 11-50 Employees
Phone Number: 61********
Who is LONGBOARD PHARMACEUTICALS
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard is working to adva...
Read More
-
Headquarters: 4275 Executive Sq, La Jolla, California, 92037, United States
-
Date Founded: 2020
-
Employees: 11-50
-
Revenue: $10 Million to $25 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 8731
|
NAICS Code: 541714 |
Show More
Does something look wrong? Fix it. | View contact records from LONGBOARD PHARMACEUTICALS
Longboard Pharmaceuticals Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Longboard Pharmaceuticals
Answer: Longboard Pharmaceuticals's headquarters are located at 4275 Executive Sq, La Jolla, California, 92037, United States
Answer: Longboard Pharmaceuticals's phone number is 61********
Answer: Longboard Pharmaceuticals's official website is https://longboardpharma.com
Answer: Longboard Pharmaceuticals's revenue is $10 Million to $25 Million
Answer: Longboard Pharmaceuticals's SIC: 8731
Answer: Longboard Pharmaceuticals's NAICS: 541714
Answer: Longboard Pharmaceuticals has 11-50 employees
Answer: Longboard Pharmaceuticals is in Biotechnology
Answer: Longboard Pharmaceuticals contact info: Phone number: 61******** Website: https://longboardpharma.com
Answer: Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboards small molecule product candidates are based on more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies. Longboard is also evaluating LP659, a centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, in development for the potential treatment of multiple neurological diseases, and LP143, a centrally acting, full cannabinoid type 2 receptor (CB2) agonist, in development for the potential treatment of central nervous system (CNS) diseases and disorders.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month